Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease |
| |
| Authors: | Helena Iznardo Lluís Puig |
| |
| Affiliation: | 1.Dermatology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain;2.Department of Medicine, School of Medicine, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain |
| |
| Abstract: | Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results. |
| |
| Keywords: | psoriasis pustular psoriasis psoriatic arthritis imsidolimab spesolimab IL-36 IL-36R pathogenesis |
|
|
